JNM

@JournalofNucMed

The journal of the Society of Nuclear Medicine and Molecular Imaging. Clinical investigations, basic science reports, continuing education articles and more.

Joined October 2020

167Following

4KFollowers

JNM@JournalofNucMed · Jul 25

Can a quantitative extension of the visual 5-point Deauville scale, known as qPET, allow for better prognostic discrimination? Read more: ow.ly/x5Mg50WoMfz #NuclearMedicine #NonHodgkinLymphoma #PETscan @JamieFlerlage @LopciEgesta

JournalofNucMed's tweet image. Can a quantitative extension of the visual 5-point Deauville scale, known as qPET, allow for better prognostic discrimination? Read more: ow.ly/x5Mg50WoMfz

#NuclearMedicine #NonHodgkinLymphoma #PETscan @JamieFlerlage @LopciEgesta

863

JNM@JournalofNucMed · Jul 24

PYTA is a promising chelator for ²²⁵Ac, comparable to MACROPA, with the advantages of modular bifunctional chelator synthesis. ow.ly/z0lA50WoMfb #NuclearMedicine #RPTherapy #Theranostics

JournalofNucMed's tweet image. PYTA is a promising chelator for ²²⁵Ac, comparable to MACROPA, with the advantages of modular bifunctional chelator synthesis. ow.ly/z0lA50WoMfb

#NuclearMedicine #RPTherapy #Theranostics

569

JNM@JournalofNucMed · Jul 23

Normalization of PET images to account for blood levels enhanced the detection of TREM2. This improved methodology provides a promising basis for future assessments of TREM2 imaging. ow.ly/KI2k50WoMeN #NuclearMedicine #PETscan @matbrendel @Haass_Lab

JournalofNucMed's tweet image. Normalization of PET images to account for blood levels enhanced the detection of TREM2. This improved methodology provides a promising basis for future assessments of TREM2 imaging. ow.ly/KI2k50WoMeN

#NuclearMedicine #PETscan @matbrendel @Haass_Lab

499

JNM@JournalofNucMed · Jul 22

Reply to “Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals.” ow.ly/jB9250WoMes #Nuclearmedicine #PETscan #Dosimetry @Scott_LabUM @PET_Drugs @SallyWSchwarz @mdakanali @FDA

400

JNM@JournalofNucMed · Jul 22

Letter to the Editor: Foregoing nonclinical dosimetry studies to support first-in-human studies of certain PET radiopharmaceuticals. ow.ly/MhLj50WoMci #Nuclearmedicine #PETscan #Dosimetry @FDA

620

JNM@JournalofNucMed · Jul 21

SNMMI Annual Meeting Flashback: Johannes Czernin and Richard Wahl discuss trending topics in nuclear medicine. ow.ly/Fz2h50WocuN #NuclearMedicine #MolecularImaging #Theranostics #SNMMI25

JournalofNucMed's tweet image. SNMMI Annual Meeting Flashback: Johannes Czernin and Richard Wahl discuss trending topics in nuclear medicine. ow.ly/Fz2h50WocuN

#NuclearMedicine #MolecularImaging #Theranostics #SNMMI25

606

JNM@JournalofNucMed · Jul 18

Continuing education: Treatment response evaluation in prostate cancer using PSMA PET/CT. ow.ly/uUgP50WocwV #NuclearMedicine #RPTherapy #ProstateCancer @liljasolnes @FrancescoCeci13 @DrAGafita

JournalofNucMed's tweet image. Continuing education: Treatment response evaluation in prostate cancer using PSMA PET/CT. ow.ly/uUgP50WocwV

#NuclearMedicine #RPTherapy #ProstateCancer @liljasolnes @FrancescoCeci13 @DrAGafita

1.0K

JNM@JournalofNucMed · Jul 16

Theranostics in Perspective: Challenges and possible solutions to avoid speed breakers in theranostics. ow.ly/OnCv50WocvY #NuclearMedicine #Theranostics #RPTherapy @ProfKHerrmann

JournalofNucMed's tweet image. Theranostics in Perspective: Challenges and possible solutions to avoid speed breakers in theranostics. ow.ly/OnCv50WocvY

#NuclearMedicine #Theranostics #RPTherapy @ProfKHerrmann

1.0K

JNM@JournalofNucMed · Jul 15

SNMMI Annual Meeting Flashback: JNM Podcast guests David Mankoff, Hossein Jadvar, and Todd Peterson answer the question: "Can society-based journals compete with corporate-based publications?” ow.ly/Oetq50Wocuo #NuclearMedicine #MolecularImaging #SNMMI25

JournalofNucMed's tweet image. SNMMI Annual Meeting Flashback: JNM Podcast guests David Mankoff, Hossein Jadvar, and Todd Peterson answer the question: "Can society-based journals compete with corporate-based publications?” ow.ly/Oetq50Wocuo

#NuclearMedicine #MolecularImaging #SNMMI25

537

JNM@JournalofNucMed · Jul 14

SNMMI Annual Meeting Flashback: In this JNM Podcast episode, Johannes Czernin interviews Anna Karmann to talk about the various career trajectories at the interface of industry and academia. ow.ly/nPhR50WoctM #NuclearMedicine #SNMMI25

JournalofNucMed's tweet image. SNMMI Annual Meeting Flashback: In this JNM Podcast episode, Johannes Czernin interviews Anna Karmann to talk about the various career trajectories at the interface of industry and academia. ow.ly/nPhR50WoctM

#NuclearMedicine #SNMMI25

390

JNM@JournalofNucMed · Jul 11

JNM’s 2024 Editor’s Choice award for best basic science article goes to Kyeara N. Mack, Memorial Sloan Kettering Cancer Center, and coauthors for “Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer.” ow.ly/6emk50WocsK

JournalofNucMed's tweet image. JNM’s 2024 Editor’s Choice award for best basic science article goes to Kyeara N. Mack, Memorial Sloan Kettering Cancer Center, and coauthors for “Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer.” ow.ly/6emk50WocsK

372

JNM@JournalofNucMed · Jul 11

JNM’s 2024 Editor’s Choice award for best clinical article goes to Hongdi Li, United Imaging Health Care North America, and colleagues for “Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager.” ow.ly/NwHF50Woco3

JournalofNucMed's tweet image. JNM’s 2024 Editor’s Choice award for best clinical article goes to Hongdi Li, United Imaging Health Care North America, and colleagues for “Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager.” ow.ly/NwHF50Woco3

543

JNM@JournalofNucMed · Jul 8

¹⁷⁷Lu-DOTATATE is cost-effective as a first-line treatment for patients with grade 2 or 3, well-differentiated, advanced gastroenteropancreatic #NeuroendocrineTumors. ow.ly/Zzw150W9YMP #NuclearMedicine @WolfgangGKunzMD @MUnterrainerMD @matbrendel @UnterrainerLena

JournalofNucMed's tweet image. ¹⁷⁷Lu-DOTATATE is cost-effective as a first-line treatment for patients with grade 2 or 3, well-differentiated, advanced gastroenteropancreatic #NeuroendocrineTumors. ow.ly/Zzw150W9YMP

#NuclearMedicine @WolfgangGKunzMD @MUnterrainerMD @matbrendel
@UnterrainerLena

3.0K

JNM@JournalofNucMed · Jul 7

In preclinical models of advanced human #BreastCancer, treatment with optimized ²²⁵Ac-PRIT can result in a high probability of complete responses & durable tumor responses, including histologic cures. ow.ly/kCVX50W9YIV #NuclearMedicine @SaraRinne @ChealLab

JournalofNucMed's tweet image. In preclinical models of advanced human #BreastCancer, treatment with optimized ²²⁵Ac-PRIT can result in a high probability of complete responses &amp; durable tumor responses, including histologic cures. ow.ly/kCVX50W9YIV

#NuclearMedicine @SaraRinne @ChealLab

720

JNM@JournalofNucMed · Jul 4

Short-term tyrosine kinase inhibitor therapy is a feasible approach for restoring iodine uptake in selected patients with metastatic radioactive iodine–refractory thyroid cancer. ow.ly/t99q50W9YHB #NuclearMedicine #ThyroidCancer #RPTherapy

$JournalofNucMed's tweet image. Short-term tyrosine kinase inhibitor therapy is a feasible approach for restoring iodine uptake in selected patients with metastatic radioactive iodine–refractory thyroid cancer. ow.ly/t99q50W9YHB #NuclearMedicine #ThyroidCancer #RPTherapy$

1.0K

JNM@JournalofNucMed · Jul 3

Efficacy, safety, blood kinetics, and ²¹³Bi distribution studies of ²²⁵Ac-SibuDAB in prostate cancer patients: ow.ly/LxG950W9YGM #NuclearMedicine #RPTherapy #ProstateCancer

JournalofNucMed's tweet image. Efficacy, safety, blood kinetics, and ²¹³Bi distribution studies of ²²⁵Ac-SibuDAB in prostate cancer patients: ow.ly/LxG950W9YGM

#NuclearMedicine #RPTherapy #ProstateCancer

990

JNM@JournalofNucMed · Jul 2

A new reporting and data system framework is proposed to standardize FAP-targeted imaging reports, improve clinical communication, and support multicenter research. ow.ly/U0Oo50W9YEt #NuclearMedicine #PETscan @ProfKHerrmann @radnucmp @michael_gorin

JournalofNucMed's tweet image. A new reporting and data system framework is proposed to standardize FAP-targeted imaging reports, improve clinical communication, and support multicenter research. ow.ly/U0Oo50W9YEt

#NuclearMedicine #PETscan @ProfKHerrmann @radnucmp @michael_gorin

921

JNM@JournalofNucMed · Jul 1

¹⁸F-CTT1057 is effective in detecting PSMA-positive lesions, with high patient-level sensitivity and region-level specificity. ow.ly/uBa150W9YBZ #NuclearMedicine #MolecularImaging #ProstateCancer @stefanofanti4 @FrancescoCeci13 @NBuffi @PilarParedesMN

JournalofNucMed's tweet image. ¹⁸F-CTT1057 is effective in detecting PSMA-positive lesions, with high patient-level sensitivity and region-level specificity. ow.ly/uBa150W9YBZ

#NuclearMedicine #MolecularImaging #ProstateCancer @stefanofanti4 @FrancescoCeci13 @NBuffi @PilarParedesMN

676

JNM@JournalofNucMed · Jun 30

What is the mean radiation dose that should be targeted in colorectal carcinoma liver metastases in TARE with ⁹⁰Y glass microspheres? Find out: ow.ly/kC5G50W1AuI #NuclearMedicine #Dosimetry #ColorectalCancer @fcpiskin @CigdemSoydal

JournalofNucMed's tweet image. What is the mean radiation dose that should be targeted in colorectal carcinoma liver metastases in TARE with ⁹⁰Y glass microspheres? Find out: ow.ly/kC5G50W1AuI

#NuclearMedicine #Dosimetry #ColorectalCancer @fcpiskin @CigdemSoydal

628

JNM@JournalofNucMed · Jun 27

Retreatment with ²²³Ra is both safe and effective in patients with bone-metastatic metastatic castration-resistant prostate cancer. ow.ly/glsm50W1AqS #NuclearMedicine #RPTherapy #ProstateCancer @maartenvddoelen

JournalofNucMed's tweet image. Retreatment with ²²³Ra is both safe and effective in patients with bone-metastatic metastatic castration-resistant prostate cancer. ow.ly/glsm50W1AqS

#NuclearMedicine #RPTherapy #ProstateCancer @maartenvddoelen

1.0K